Immunovia completes development of its pancreatic cancer detection test after substantially increasing test accuracy
LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces enhanced performance for its next-generation test for detecting stage 1 and 2 pancreatic ductal adenocarcinomas (PDAC) in high-risk individuals, which are potentially curable with surgery and modern treatments. On 22 April 2024 , Immunovia announced positive results from the initial model-development study for its